menu search

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid tumors harboring RAS mutations CAMBRIDGE, Mass., March 05, 2023 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients […] The post Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Support... Read More
Posted: Mar 5 2023, 23:30
Author Name: forextv
Views: 082182

Search within

Pages Search Results: